OCULUS INC (OVTZ) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 8, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the OVTZ SEC filings page.
This page shows OCULUS INC (OVTZ) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Reported figures describe a shrinking, heavily impaired balance sheet, while sparse operating data prevents judging a functioning revenue engine.
The clearest earnings-quality signal is the mismatch between 2023 net income of$589K and operating cash flow of-$533K : reported profit did not arrive as cash. By 2025, operating cash flow turned positive at$7K , but liabilities had climbed to$770K as assets fell to$32K , so the cash-flow improvement did not translate into a stronger financial base.
Balance-sheet deterioration is the dominant pattern: assets fell from
The operating footprint cannot be evaluated through normal margin or growth lenses because revenue, gross profit, and free cash flow are not reported. Research and development spending fell from
Financial Health Signals
OCULUS INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
OCULUS INC reported -$63K in net income in Q2 2026. This represents a decrease of 21.0% from the same quarter a year earlier. Against the prior quarter it is down 0.8%.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
OCULUS INC held $5K in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
None of these metrics is reported for Q2 2026.
Capital Allocation
OCULUS INC invested $276 in research and development in Q2 2026. This represents an increase of 50.8% from the same quarter a year earlier. Against the prior quarter it is up 2.2%.
Not reported for Q2 2026.
Not reported for Q2 2026.
OVTZ Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $276+50.8% | $270-2.5% | N/A | $276-81.0% | $183-92.8% | $277-87.3% | N/A | $1K-68.5% |
| SG&A Expenses | $47K+29.1% | $47K-46.6% | N/A | $78K+50.9% | $37K-20.5% | $88K+85.7% | N/A | $52K-34.7% |
| Net Income | -$63K-21.0% | -$62K+39.7% | N/A | -$93K-34.7% | -$52K+35.3% | -$103K-24.3% | N/A | -$69K+50.8% |
| EPS (Basic) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Operating Income, EBITDA, Interest Expense, Income Tax, EPS (Diluted), Diluted Shares (Avg).
OVTZ Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $21K-10.3% | $36K-17.8% | $32K-18.6% | $25K+51.9% | $24K-47.0% | $44K-60.4% | $40K-78.5% | $17K-93.3% |
| Cash & Equivalents | $5K-39.1% | $17K+105.8% | $9K-19.7% | $15K+336.9% | $8K-72.4% | $8K-91.5% | $12K-92.5% | $3K-98.5% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $871K+46.2% | $829K+49.0% | $770K+71.5% | $692K+107.7% | $596K+104.0% | $556K+99.4% | $449K+64.0% | $333K+31.6% |
| Current Liabilities | $871K+46.2% | $829K+49.0% | $770K+71.5% | $692K+107.7% | $596K+104.0% | $556K+99.4% | $449K+64.0% | $333K+31.6% |
| Non-Current Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Equity | -$850K-48.5% | -$793K-54.7% | -$738K-80.2% | -$667K-110.7% | -$572K-131.4% | -$513K-203.8% | -$409K-356.1% | -$317K-5002.9% |
| Retained Earnings | -$49.2M-0.6% | -$49.1M-0.6% | -$49.0M-0.7% | -$49.0M-0.7% | -$48.9M-0.7% | -$48.8M-0.7% | -$48.7M-0.7% | -$48.6M-0.7% |
Not reported in any period shown, so not listed: Current Assets, Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
OVTZ Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
OVTZ Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Current Ratio, Debt-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$738K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| OCULUS INC OVTZ | FY2025 | N/A | N/A | N/A | $2.8M | — |
| INNOVATIVE PYMNT SOLUTION IPSI | FY2025 | N/A | -$4.4M | N/A | $597K | — |
| VISIUM TECHNOLOGIES INC VISM | FY2025 | $0 | N/A | N/A | $592 | — |
Where OCULUS INC Ranks
Frequently Asked Questions
What is OCULUS INC's operating cash flow?
OCULUS INC (OVTZ) generated $7K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are OCULUS INC's total assets?
OCULUS INC (OVTZ) had $32K in total assets as of fiscal year 2025, including both current and long-term assets.
How much does OCULUS INC spend on research and development?
OCULUS INC (OVTZ) invested $1K in research and development during fiscal year 2025.
What is OCULUS INC's P/E ratio?
OCULUS INC (OVTZ) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $2.8M as of Oct 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is OCULUS INC's price-to-sales ratio?
OCULUS INC (OVTZ) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $2.8M as of Oct 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Why is OCULUS INC's debt-to-equity ratio negative or not reported?
OCULUS INC (OVTZ) has negative shareholder equity of -$738K as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.